NEW YORK, NY / ACCESSWIRE / December 29, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA). Investors who purchased Iovance securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IOVA.
Investigation Details:
On December 27, 2023, Iovance announced that, on December 22, 2023, the U.S. Food and Drug Administration ("FDA") had placed a clinical hold on the Company's IOV-LUN-202 trial, which was investigating the Company's lead product candidate for the treatment of metastatic non-small cell lung cancer. Iovance advised that the FDA's decision to place the clinical hold was "in response to a recently reported Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen." On this news, Iovance's stock price fell $1.66 per share, or 18.67%, to close at $7.23 per share on December 27, 2023.
What's Next?
If you are aware of any facts relating to this investigation or purchased Iovance securities, you can assist this investigation by visiting the firm's site: bgandg.com/IOVA. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original
press release on accesswire.com
